The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort
Abstract
Purpose: Studies suggest eicosapentaenoic acid (EPA), an omega-3 fatty acid, augments weight, appetite, and survival in cancer-associated wasting. This study determined whether an EPA supplement—administered alone or with megestrol acetate (MA)—was more effective than MA. Patients and Methods: Four hundred twenty-one assessable patients with cancer-associated wasting were randomly assigned to an EPA supplement 1.09 g administered bid plus placebo; MA liquid suspension 600 mg/d plus an isocaloric, isonitrogenous supplement administered twice a day; or both. Eligible patients reported a 5-lb, 2-month weight loss and/or intake of less than 20 calories/kg/d. Results: A smaller percentage taking the EPA supplement gained ≥ 10% of baseline weight compared with those taking MA: 6% v 18%, respectively (P = .004). Combination therapy resulted in weight gain of ≥ 10% in 11% of patients (P = .17 across all arms). The percentage of patients with appetite improvement (North Central Cancer Treatment Group Questionnaire) was not statistically different: 63%, 69%, and 66%, in EPA-, MA-, and combination-treated arms, respectively (P = .69). In contrast, 4-week Functional Assessment of Anorexia/Cachexia Therapy scores suggested MA-containing arms experienced superior appetite stimulation compared with the EPA arm, with scores of 40, 55, and 55 in EPA-, MA-, and combination-treated arms, respectively (P = .004). Survival was not significantly different among arms. Global quality of life was not significantly different among groups. With the exception of increased impotence in MA-treated patients, toxicity was comparable. Conclusion: This EPA supplement, either alone or in combination with MA, does not improve weight or appetite better than MA alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
Statistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652
The method of minimization for allocation to clinical trials
Scott, N. W., McPherson, G. C., Ramsay, C. R., & Campbell, M. K. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00242-8 · Cited by 651
Walsh, D., Donnelly, S., & Rybicki, L. (2000) · Supportive Care in Cancer · doi:10.1007/s005200050281 · Cited by 623
Fearon, K. C. H. (2003) · Gut · doi:10.1136/gut.52.10.1479 · Cited by 603
Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., Pundaleeka, S., Kardinal, C. G., Fitch, T. R., Krook, J. E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.567 · Cited by 543
Self-citationBarber, M. D., Ross, J. A., Voss, A. C., Tisdale, M. J., & Fearon, K. C. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690654 · Cited by 459
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., Krook, J. E., Wilwerding, M. B., Rowland, K. M., Camoriano, J. K., Novotny, P. J., & Christensen, B. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3299 · Cited by 343
Self-citationControlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
Loprinzi, C. L., Ellison, N. M., Schaid, D. J., Krook, J. E., Athmann, L. M., Dose, A. M., Mailliard, J. A., Johnson, P. S., Ebbert, L. P., & Geeraerts, L. H. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1127 · Cited by 318
Self-citation
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., van Bokhorst-de van der Schueren, M. A. E., von Meyenfeldt, M., Zürcher, G., Fietkau, R., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.020 · Cited by 930
Cachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
August, D. A., Huhmann, M. B., & the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors (2009) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607109341804 · Cited by 516
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Metadata
- Authors
- Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., Gagnon, B., Novotny, P. J., Mailliard, J. A., Bushey, T. I. L., Nair, S., & Christensen, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-15
- Volume
- 22
- Issue
- 12
- Pages
- 2469-2476
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120629110
- Cited by
- 296
- References
- 26
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. https://app.cochat.ai/papers/10.1200/jco.2004.06.024
- The paper
- Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., Gagnon, B., Novotny, P. J., Mailliard, J. A., Bushey, T. I. L., Nair, S., & Christensen, B. (2004). An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.06.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.